Do analysts rate ABVC or IMNN?

Imunon has a consensus target price of $10.00, suggesting a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ABVC or IMNN more profitable?

ABVC BioPharma's return on equity of -62.46% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Imunon N/A -341.23% -153.79%

Does the media favor ABVC or IMNN?

In the previous week, Imunon had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Imunon and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.59 beat Imunon's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ATHA or IMNN?

Athira Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$96.94M -$9.68 N/A Imunon N/A N/A -$14.49M -$5.16 N/A

Is ATHA or IMNN more profitable?

Athira Pharma's return on equity of -107.06% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -107.06% -89.89% Imunon N/A -341.23% -153.79%

Do analysts prefer IMNN or GRDX?

Imunon presently has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IMNN or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Entero Therapeutics N/A -49.81% -11.02%

Do analysts recommend IMNN or CPHI?

Imunon currently has a consensus target price of $10.00, indicating a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, equities research analysts clearly believe Imunon is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IMNN or CPHI more profitable?

Imunon has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% China Pharma -85.56% -63.93% -31.42%

Does the media prefer IMNN or CPHI?

In the previous week, China Pharma had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for China Pharma and 2 mentions for Imunon. China Pharma's average media sentiment score of 0.19 beat Imunon's score of 0.00 indicating that China Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Imunon 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNN or ALGS more profitable?

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity. Company Net Margins Return on Equity Return on Assets Imunon N/A -341.23% -153.79% Aligos Therapeutics -1,919.68% -139.47% -90.88%

Imunon (IMNN) Competitors

$1.78 -0.02 (-1.11%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.10 (+5.51%)

As of 08:37 AM Eastern

Compare

IMNN vs. ABVC, ATHA, GRDX, CPHI, and ALGS

Should you buy Imunon stock or one of its competitors? MarketBeat compares Imunon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Imunon include ABVC BioPharma (ABVC), Athira Pharma (ATHA), Entero Therapeutics (GRDX), China Pharma (CPHI), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.

How does Imunon compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

ABVC BioPharma's return on equity of -62.46% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Imunon	N/A	-341.23%	-153.79%

ABVC BioPharma has higher revenue and earnings than Imunon. ABVC BioPharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	66.78	-$7.91M	-$0.40	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

Imunon has a consensus target price of $10.00, suggesting a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Imunon had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Imunon and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.59 beat Imunon's score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ABVC BioPharma has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Imunon has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 2.8% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ABVC BioPharma beats Imunon on 8 of the 14 factors compared between the two stocks.

How does Imunon compare to Athira Pharma?

Athira Pharma (NASDAQ:ATHA) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Athira Pharma currently has a consensus target price of $4.00, suggesting a potential downside of 51.34%. Imunon has a consensus target price of $10.00, suggesting a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athira Pharma's return on equity of -107.06% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Imunon	N/A	-341.23%	-153.79%

Athira Pharma has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, Imunon has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Athira Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94M	-$9.68	N/A
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A

In the previous week, Imunon had 2 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 0.00 equaled Imunon'saverage media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
Imunon	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by insiders. Comparatively, 2.8% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Imunon beats Athira Pharma on 7 of the 12 factors compared between the two stocks.

How does Imunon compare to Entero Therapeutics?

Imunon (NASDAQ:IMNN) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Entero Therapeutics has higher revenue and earnings than Imunon. Entero Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Entero Therapeutics	$74.46K	411.02	-$6.39M	-$1.88	N/A

In the previous week, Imunon had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Entero Therapeutics. Imunon's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
Imunon	Neutral
Entero Therapeutics	Neutral

Imunon presently has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, analysts plainly believe Imunon is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Imunon has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

4.5% of Imunon shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 2.8% of Imunon shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entero Therapeutics' return on equity of -49.81% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Imunon beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Imunon compare to China Pharma?

Imunon (NASDAQ:IMNN) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, China Pharma had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for China Pharma and 2 mentions for Imunon. China Pharma's average media sentiment score of 0.19 beat Imunon's score of 0.00 indicating that China Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Imunon	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
China Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Imunon has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Imunon has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
China Pharma	-85.56%	-63.93%	-31.42%

China Pharma has higher revenue and earnings than Imunon. China Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
China Pharma	$3.99M	7.06	-$3.08M	-$0.55	N/A

4.5% of Imunon shares are owned by institutional investors. 2.8% of Imunon shares are owned by company insiders. Comparatively, 6.4% of China Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Imunon currently has a consensus target price of $10.00, indicating a potential upside of 461.80%. Given Imunon's stronger consensus rating and higher possible upside, equities research analysts clearly believe Imunon is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

China Pharma beats Imunon on 8 of the 15 factors compared between the two stocks.

How does Imunon compare to Aligos Therapeutics?

Imunon (NASDAQ:IMNN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

Imunon has higher earnings, but lower revenue than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$14.49M	-$5.16	N/A
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A

In the previous week, Imunon had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Aligos Therapeutics. Imunon's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Imunon	Neutral
Aligos Therapeutics	Neutral

Imunon currently has a consensus price target of $10.00, indicating a potential upside of 461.80%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 581.42%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Imunon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

4.5% of Imunon shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 2.8% of Imunon shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Imunon has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Imunon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-341.23%	-153.79%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Imunon has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

Summary

Aligos Therapeutics beats Imunon on 10 of the 15 factors compared between the two stocks.

Get Imunon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMNN vs. The Competition

Export

Metric	Imunon	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.56M	$3.45B	$6.44B	$12.30B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-0.34	19.75	24.66	23.99
Price / Sales	N/A	329.51	531.91	108.06
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.77	8.29	10.81	6.50
Net Income	-$14.49M	$23.85M	$3.56B	$336.88M
7 Day Performance	-4.30%	2.87%	0.93%	-0.16%
1 Month Performance	-19.09%	2.19%	0.35%	0.76%
1 Year Performance	-86.63%	55.48%	29.69%	28.49%

Imunon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMNN Imunon	3.0961 of 5 stars	$1.78 -1.1%	$10.00 +461.8%	-87.1%	$7.56M	N/A	N/A	30	News Coverage
ABVC ABVC BioPharma	0.9078 of 5 stars	$1.29 +2.4%	N/A	-33.2%	$32.76M	$510K	N/A	30	News Coverage Positive News Gap Down High Trading Volume
ATHA Athira Pharma	N/A	$8.22 -4.5%	$4.00 -51.3%	+177.7%	$32.42M	N/A	N/A	40
GRDX Entero Therapeutics	0.1986 of 5 stars	$5.09 +4.7%	N/A	N/A	$32.33M	$40K	N/A	9	Positive News
CPHI China Pharma	N/A	$0.78 +2.3%	N/A	-58.6%	$31.69M	$3.99M	N/A	250	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMNN) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Imunon (IMNN) Competitors

IMNN vs. ABVC, ATHA, GRDX, CPHI, and ALGS

How does Imunon compare to ABVC BioPharma?

Summary

How does Imunon compare to Athira Pharma?

Summary

How does Imunon compare to Entero Therapeutics?

Summary

How does Imunon compare to China Pharma?

Summary

How does Imunon compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Imunon (IMNN) Competitors

IMNN vs. ABVC, ATHA, GRDX, CPHI, and ALGS

How does Imunon compare to ABVC BioPharma?

Is ABVC or IMNN more profitable?

Which has stronger earnings & valuation, ABVC or IMNN?

Do analysts rate ABVC or IMNN?

Does the media favor ABVC or IMNN?

Which has more risk and volatility, ABVC or IMNN?

Do insiders & institutionals hold more shares of ABVC or IMNN?

Summary

How does Imunon compare to Athira Pharma?

Do analysts prefer ATHA or IMNN?

Is ATHA or IMNN more profitable?

Which has more volatility and risk, ATHA or IMNN?

Which has stronger earnings & valuation, ATHA or IMNN?

Does the media refer more to ATHA or IMNN?

Do institutionals & insiders hold more shares of ATHA or IMNN?

Summary

How does Imunon compare to Entero Therapeutics?

Which has better valuation & earnings, IMNN or GRDX?

Does the media refer more to IMNN or GRDX?

Do analysts prefer IMNN or GRDX?

Which has more risk & volatility, IMNN or GRDX?

Do insiders & institutionals hold more shares of IMNN or GRDX?

Is IMNN or GRDX more profitable?

Summary

How does Imunon compare to China Pharma?

Does the media prefer IMNN or CPHI?

Which has more risk & volatility, IMNN or CPHI?

Is IMNN or CPHI more profitable?

Which has preferable earnings & valuation, IMNN or CPHI?

Do institutionals & insiders have more ownership in IMNN or CPHI?

Do analysts recommend IMNN or CPHI?

Summary

How does Imunon compare to Aligos Therapeutics?

Which has stronger earnings and valuation, IMNN or ALGS?

Does the media prefer IMNN or ALGS?

Do analysts rate IMNN or ALGS?

Do insiders & institutionals have more ownership in IMNN or ALGS?

Is IMNN or ALGS more profitable?

Which has more risk & volatility, IMNN or ALGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMNN vs. The Competition

Imunon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools